Anca D. Askanase, MD, MPH

Expertise in: 
Lupus, Vasculitis, Sjogren's Syndrome
Board Certifications: 
Rheumatology
Accepting New Patients
Profile Headshot

Overview

Areas of Expertise / Conditions Treated

Vasculitis, Sjogren's Syndrome, Lupus, Rheumatology, Rheumatic Disease, Arthritis, Rheumatoid, Systemic Lupus Erythematosus

Academic Appointments

  • Associate Professor of Medicine at CUMC

Anca D. Askanase, MD, MPH – ColumbiaDoctors Rheumatologist

Dr. Anca Dinu Askanase recently joined the CUMC Rheumatology faculty where she is the founder and clinical director of Columbia's new Lupus Center and the Director of Rheumatology Clinical Trials. Dr. Askanase is an internationally renowned clinician, diagnostician and researcher with more than 15 years specializing in complex Systemic Lupus Erythematosus (SLE). Dr. Askanase trained as a rheumatologist at New York University where she remained for more than 15 years on faculty, directing clinical trials, training fellows and residents, and treating challenging cases of SLE at NYU's prestigious Hospitals.

Dr. Askanase's academic career has focused primarily on the care of patients with SLE and other autoimmune diseases.In order to provide better care for patients suffering from these devastating diseases, she embarked on a journey of research and discovery, with the goal of understanding disease outcomes from both the patients' and physicians' perspective while helping to redefine 21st century therapeutic options. It is Dr. Askanase's hope that by helping to establish widely accepted parameters for quantifying the impact of the disease and the response to medications, all doctors will have effective benchmarks and therapeutic options to better treat patients with SLE's often confounding symptoms.

In addition to numerous publications and benchmark clinical trials, Dr. Askanase is a member of the two major international consortia aimed at providing the collaboration between lupus doctors needing to improve outcomes and therapies in Lupus: the SLICC (SLE international Collaborating Clinics) and the LNTN (Lupus Nephritis Trial Network).Dr. Askanase believes that excellent care often involves bringing novel therapies to her patients with Lupus and other autoimmune diseases; thus, she has been involved in every major SLE clinical drug trial and multiple NIH and industry sponsored clinical trials. One of her most rewarding experiences was her involvement as the Site Principal Investigator in the registrational study that led to the FDA approval of Belimumab, the first new Lupus drug in over 50 years. Dr. Askanase also designed and executed the only study looking at a rational approach (based on pharmacogenetics and metabolite measurement) to use Azathioprine in the treatment of Lupus. She is currently evaluating the use of ACTH as a steroid alternative in lupus nephritis. Dr. Askanase is also a proud Columbia Alumnus and still lives in Morningside Heights with her husband and two children.

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Languages

  • French
  • Romanian
  • Spanish

Gender

  • Female

Schedule an Appointment

Phone Appointments

New and Existing Patients:
212-305-4308

Location(s)

CUMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Primary
ColumbiaDoctors Midtown
51 West 51st Street
New York, NY 10019

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • POS
  • PPO

Local 1199

  • Local 1199

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • EPO
  • HMO
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • MPH, Columbia University, Mailman School of Public Health
  • 1989 Instit De Medicina Si Farmacie Carol Davila
  • MD, Institute of Medicine and Pharmacy-Carol Davilla (Romania)
  • 2003 Columbia University School of Public Health
  • Internship: St. Lukes Roosevelt Hospital Center
  • Residency: St. Lukes Roosevelt Hospital Center
  • Fellowship: Hospital for Joint Diseases

Board Certifications

  • Rheumatology
America's Top Doctor

Research

As a lupus physician and investigator previously at New York University School of Medicine/NYU Hospital for Joint Diseases, Dr. Askanase gained extensive experience with SLE patients, established a lupus cohort and participated in multiple lupus clinical trials. At Columbia, she founded and currently directs the Columbia University Lupus Center and serves as the Director of Rheumatology Clinical Trials. Dr. Askanase has identified all of the patients followed at the Columbia University Medical Center and established a new cohort of SLE patients that includes a large number of Hispanic patients of Dominican origin and allows for multiple observational studies addressing SLE activity and damage. Lupus patients move seamlessly from clinical care into NIH, investigator initiated and industry sponsored therapeutic SLE clinical trials that ensure access to promising new medications and excellent care. Dr. Askanase's experience at NYU and Columbia has highlighted the heterogeneity and complexity of SLE and the need for comprehensive care for lupus patients as well as simple and efficient SLE disease activity measures. Her group is in the process of establishing a patient-centered medical home system for the care of lupus patients that provides easy around-the-clock access to a heath care provider for all lupus patients in the hope of decreasing emergency room visits and hospitalizations in high-risk lupus patients.  In collaboration with the Lupus Foundation of America, they have developed a simple and easy-to-use outcome measure that includes both the physician and patient’s perspective.  This outcome measure could inform the tailoring of medication regimens in clinical trials and in clinical care in order to achieve low disease activity and remission in SLE.  

Grants

A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 104-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BELIMUMAB ADMINISTERED IN COMBINATION WITH RITUXIMAB TO ADULT SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (P&S Industry Clinical Trial)

Jul 30 2018 - Jul 30 2023

A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (P&S Industry Clinical Trial)

Nov 14 2017 - Nov 14 2022

A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF H.P. ACTHAR? GEL IN SUBJECTS WITH PERSISTENTLY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE MODERATE DOSE CORTICOSTEROIDS (P&S Industry Clinical Trial)

May 11 2017 - May 11 2022

A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 EXTENSION STUDY TO CHARACTERISE THE LONG-TERM SAFETY AND TOLERABILITY OF ANIFROLUMAB IN ADULT SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (P&S Industry Clinical Trial)

Apr 27 2017 - Apr 27 2022

A PILOT, PHASE 2, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE BLIND, STUDY TO EVALUATE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PHARMACOGENETICS OF CC- 220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (P&S Industry Clinical Trial)

Jan 20 2015 - Jan 20 2020

SIGNIFICANCE OF INTRARENAL T CELLS IN SLE NEPHRITIS (Federal Gov)

Jan 25 2016 - Dec 31 2019

DYNAMIC IMAGING OF VARIATION IN LUPUS NEPHRITIS (Private)

Oct 8 2018 - Oct 7 2019

A PHASE 1B, RANDOMIZED, DOUBLE BLIND, PLACEBO- CONTROLLED, SAFETY, TOLERABILITY, AND PHARMACOKINETIC STUDY OF MULTIPLE RISING DOSES OF MLN9708 FOR THE TREATMENT OF SUBJECTS WITH ISN/ RPS CLASS III OR IV LUPUS NEPHRITIS (P&S Industry Clinical Trial)

Sep 29 2014 - Sep 29 2019

PHASE I ? OPEN-LABEL PROSPECTIVE RANDOMIZED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF TWO DOSING REGIMENS OF ACTHAR IN THE TREATMENT OF PROLIFERATIVE LUPUS NEPHRITIS (P&S Industry Clinical Trial)

Aug 5 2014 - Aug 5 2019

A PHASE 3/4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BELIMUMAB (HGS1006) IN ADULT SUBJECTS OF BLACK RACE WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (P&S Industry Clinical Trial)

Jul 17 2014 - Jul 17 2019

CANCER RISK (Private)

Jun 29 2015 - Jun 28 2019

THE ROLE OF CELL BOUND COMPLEMENT ACTIVATION PRODUCTS (CBCAPS) IN DIFFERENTIATING BETWEEN SYSTEMIC LUPUS ERYTHEMATOUS (SLE), FIBROMYALGIA (FM) AND SJOGREN?S SYNDROME (SS) (P&S Industry Clinical Trial)

Mar 12 2014 - Mar 12 2019

RITUXIMAB PLUS CYCLOPHOSPHAMIDE FOLLOWED BY BELIMIMAB FOR THE TREATMENT OF LUPUS NEPHRITIS (Federal Gov)

Feb 1 2015 - Jan 31 2019

LUPUS CLINICAL INVESTIGATORS NETWORK (Private)

Jun 1 2016 - May 31 2018

POST APPROVAL CLINICAL EXPERIENCE WITH BENLYSTA (Private)

Dec 4 2014 - Dec 31 2017

AUTOIMMUNITY CENTER OF EXCELLENCE CLINICAL RESEARCH PROGRAM (Federal Gov)

Jan 1 2017 - Apr 30 2017

TREATMENT OF SLE WITH AJULEMIC ACID, A NON-PSYCHOACTIVE CANNABINOID DERIVATIVE (Federal Gov)

Sep 1 2015 - Aug 31 2016

NELFINAVIR IN SLE: A PILOT PHASE LLA CLINICAL TRIAL (Federal Gov)

Apr 1 2014 - May 31 2015

PRELIMINARY EVALUATION OF LFA REAL (PHYSICIAN) AND LFA-DIAL (PATIENT) INDICES FOR LUPUS DSEASE ACTIVITY (Private)

May 1 2014 - May 1 2015